Research and Markets - Global CRISPR And CRISPR-Associated (Cas) Genes Market Analysis 2014-2017 & 2025: Focus on Genome Engineering, Disease Models, Functional Genomics

News provided by

Research and Markets

24 Apr, 2017, 23:30 GMT

DUBLIN, April 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "CRISPR And CRISPR-Associated (Cas) Genes Market Analysis By Product (Vector-Based & DNA-Free Cas), By Application (Genome Engineering, Disease Models, Functional Genomics), By End-Use, And Segment Forecasts, 2014 - 2025" report to their offering.

The Clustered regularly interspaced short palindromic repeats CRISPR and CRISPR-associated (Cas) genes market is anticipated to reach USD 4.09 billion by 2025.

This genome editing principle spans almost every industry that involves biological systems. The rising adoption of technology in different areas associated with biotechnology is anticipated to drive industrial growth of the technology substantially in the coming years.

Possibility of rewriting the host DNA through the virtue of Cas9 by introduction of major modifications can be attributed for rising adoption of technology. These modifications include inversion, deletions, knockouts, translocations, and gene replacement.

Moreover, application of the technology as a qualitative as well as quantitative tool in plant genome editing is expected to propel growth. The technique holds the potential for producing plants with mutations linked to other disciplines of science such as disease resistance, biofuel production, synthetic biology, phytoremediation and abiotic stress tolerance.

Combination of clustered regularly interspaced short palindromic repeats and sequencing technology enables high-throughput analysis of gene regulation thereby resulting to enhancement in genomics sector. The aforementioned combination is applicable in the epigenetic study of diseases such as leukemia.

However, off-target effects associated with the implementation of CRISPR is anticipated to impede growth in the coming years. These effects include improper concentration ratio between Cas9 and single guide RNA that may result into off-target cleavage.

Further Key Findings from the Report Suggest:

  • High cost involved with mRNA and protein as compared to plasmid is attributive for larger share of vector based Cas9
  • Rapid turn-over obtained through the utilization of RNA and protein is anticipated to drive the usage of DNA free Cas9 products
  • Genome engineering dominated amongst the other applications as a consequence of higher use of Cas9 in different procedures
  • These procedures include Non-Homologous End Joining (NHEJ) and Homology Directed Repair (HDR) in plant genome editing and biomedical applications
  • Disease models and knockdown or activation are anticipated to witness hand in hand growth over the forecast period
  • Transgenic models are projected to witness lucrative growth as a result of application of technique for creation of novel in vivo neurodegenerative disease models
  • Biotechnology and pharmaceutical organizations accounted for the largest share of the market
  • These organizations are engaged in collaborating for the development of therapies using the Crispr-Cas9 gene-editing system
  • Asia Pacific is anticipated to witness lucrative growth over the forecast period.
  • The economies of this region are engaged in embarking clinical trials with the CRISPR gene-editing tool
  • Moreover, the university based projects implemented herein are attributive for the projected growth
  • Key players contributing in this market are Merck KGaA, Addgene, CRISPR THERAPEUTICS, Thermo Fisher Scientific, Inc., Mirus Bio LLC, Editas Medicine, Takara Bio USA, Horizon Discovery Group plc, GE Healthcare Dharmacon Inc, and Intellia Therapeutics, Inc.

Key Topics Covered:

1 Research Methodology

2 Executive Summary

3 CRISPR and Cas Genes Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Rising adoption in diverse fields of biotechnology
3.1.1.1.1 Epigenetics
3.1.1.1.2 Medicine
3.1.1.1.3 Human germline editing
3.1.1.1.4 Tool for qualitative and quantitative plant genome editing
3.1.1.2 Technological advancements in CRISPR technology
3.1.1.3 Introduction of anti-CRISPR protein
3.1.1.4 Ongoing competition for CRISPR commercialization
3.1.2 Market Restraint Analysis
3.1.2.1 Off-target effects of CRISPR technology
3.1.2.2 Intellectual property disputes pertaining to Cas
3.1.2.3 Ethical concerns and implications with respect to human genome editing
3.2 Penetration & Growth Prospect Mapping for Application, 2015
3.3 CRISPR and Cas Genes -Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter's
3.5 CRISPR and Cas Genes Market: Pipeline Analysis
3.5.1 Editas Medicine
3.5.2 Intellia Therapeutics, Inc.
3.5.3 CRISPR THERAPEUTICS
3.5.4 Precision Biosciences
3.5.5 Caribou Biosciences
3.5.6 Cibus
3.5.7 Recombinetics, Inc
3.6 CRISPR and Cas Genes Market: Patent Landscape

4 CRISPR and Cas Genes Market: Product Estimates & Trend Analysis
4.1 CRISPR and Cas Genes Market: Product Movement Analysis
4.2 Vector-based Cas
4.3 DNA-free Cas

5 CRISPR and Cas Genes Market: Application Estimates & Trend Analysis
5.1 CRISPR and Cas Genes Market: Application Movement Analysis
5.2 Genome Engineering
5.3 Disease Models
5.4 Functional Genomics
5.5 Knockdown/Activation
5.6 Others

6 CRISPR and Cas Genes Market: End-use Estimates & Trend Analysis
6.1 CRISPR and Cas Genes Market: End-use Movement Analysis
6.2 Biotechnology & Pharmaceutical Companies
6.3 Academic & Government Research Institutes
6.4 Contract Research Organizations (CROs)

7 CRISPR and Cas Genes Market: Regional Estimates & Trend Analysis, by Product, Application, & End-use

8 Competitive Landscape

  • Addgene
  • AstraZeneca
  • Bio-Rad Laboratories, Inc
  • Caribou Biosciences, Inc
  • Cellectis
  • Calyxt
  • Cibus
  • Nucelis
  • CRISPR THERAPEUTICS
  • Editas Medicine
  • Egenesis Inc.
  • GE Healthcare Dharmacon Inc.
  • GenScript
  • Horizon Discovery Group plc
  • Integrated DNA Technologies, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza
  • Merck KGaA
  • Sigma-Aldrich Co. LLC
  • Mirus Bio LLC
  • New England Biolabs
  • OriGene Technologies, Inc.
  • Recombinetics, Inc.
  • Takara Bio USA
  • Thermo Fisher Scientific, Inc.
  • Transposagen Biopharmaceuticals, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/bg9lth/crispr_and

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com